FDA Hepatitis Update - April 27, 2011 FDA Advisory Committee background materials available: boceprevir for Hep C

["U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: FDA Hepatitis Update - April 27, 2011 FDA Advisory Committee background materials available: boceprevir for Hep C

	 You are receiving this message as a subscriber to the FDA hepatitis electronic list serve. The purpose of the list serve is to relay important information about viral hepatitis-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.

Please do not reply to this message.

Background materials for the April 27, 2011 FDA Antiviral Advisory Committee meeting to discuss boceprevir, a direct acting antiviral (DAA) intended for the treatment of hepatitis C, are available on the FDA web site through the following links...

• April 27, 2011: Antiviral Drugs Advisory Committee Meeting Announcement   
• Draft Agenda for the April 27, 2011 Meeting of the Antiviral Drugs Advisory Committee (PDF - 42KB)   
• Draft Questions for the April 27, 2011 Meeting of the Antiviral Drugs Advisory Committee (PDF - 22KB)  
• Draft Meeting Roster for the April 27, 2011 Meeting of the Antiviral Drugs Advisory Committee (PDF - 64KB)  
• Committee Roster for the April 27, 2011 Meeting of the Antiviral Drugs Advisory Committee (PDF - 25KB)  
• Webcast Information for the April 27, 2011 Meeting of the Antiviral Drugs Advisory Committee (PDF - 16KB)
  
• Briefing Information for the April 27, 2011 Meeting of the Antiviral Drugs Advisory Committee  

Richard Klein
Office of Special Health Issues
Food and Drug Administration

Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? support@xxxxxxxxxxxxxxx
• Other inquiries? webmail@xxxxxxxxxx

U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420